Literature DB >> 2224120

All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship.

C Chomienne1, P Ballerini, N Balitrand, M T Daniel, P Fenaux, S Castaigne, L Degos.   

Abstract

All-trans retinoic acid induces leukemic cells from patients with acute promyelocytic leukemia (M3) to differentiate in vitro to mature granulocytes which express the CD15 antigen and are capable of respiratory burst function. Of 35 M3 samples, only one failed to respond. In eight cases, we compared the efficacy of two naturally occurring isomers of retinoic acid, all-trans RA and 13-cis RA. Both isomers induce maximal differentiation at 10(-6) mol/L. The maximal response was maintained at 10(-7) mol/L for the all-trans but not for the 13-cis RA. We also observed that the metabolites 4-oxo-all-trans and 4-oxo-13-cis were effective at 10(-6) mol/L. This 1 order of magnitude difference in the in vitro differentiating potencies of all-trans RA and 13-cis RA in the blasts of promyelocytic leukemias predicts a difference in the clinical efficacy of the two drugs.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2224120

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  42 in total

1.  All-trans-retinoic acid promotes trafficking of human concentrative nucleoside transporter-3 (hCNT3) to the plasma membrane by a TGF-beta1-mediated mechanism.

Authors:  Paula Fernández-Calotti; Marçal Pastor-Anglada
Journal:  J Biol Chem       Date:  2010-02-19       Impact factor: 5.157

2.  Induction of kinase suppressor of RAS-1(KSR-1) gene by 1, alpha25-dihydroxyvitamin D3 in human leukemia HL60 cells through a vitamin D response element in the 5'-flanking region.

Authors:  X Wang; T-T Wang; J H White; G P Studzinski
Journal:  Oncogene       Date:  2006-05-29       Impact factor: 9.867

3.  All-trans retinoic acid modulates the retinoic acid receptor-alpha in promyelocytic cells.

Authors:  C Chomienne; N Balitrand; P Ballerini; S Castaigne; H de Thé; L Degos
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

Review 4.  Retinoic acid syndrome. Recognition, prevention and management.

Authors:  P Fenaux; S De Botton
Journal:  Drug Saf       Date:  1998-04       Impact factor: 5.606

Review 5.  Cytokine-induced tumor suppressors: a GRIM story.

Authors:  Dhan V Kalvakolanu; Shreeram C Nallar; Sudhakar Kalakonda
Journal:  Cytokine       Date:  2010-04-10       Impact factor: 3.861

6.  Direct effects of 13-cis and all-trans retinoic acid on normal bone marrow (BM) progenitors: comparative study on BM mononuclear cells and on isolated CD34+ BM cells.

Authors:  D R van Bockstaele; M Lenjou; H W Snoeck; F Lardon; P Stryckmans; M E Peetermans
Journal:  Ann Hematol       Date:  1993-02       Impact factor: 3.673

7.  Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo. The AML Cooperative Group.

Authors:  T Haferlach; W Gassmann; H Löffler; C Jürgensen; J Noak; W D Ludwig; E Thiel; D Haase; C Fonatsch; R Becher
Journal:  Ann Hematol       Date:  1993-04       Impact factor: 3.673

8.  Repeated complete remission in a patient with acute promyelocytic leukemia after treatment with 13-cis-retinoic acid first and with all-trans-retinoic acid in relapse.

Authors:  T Haferlach; H Löffler; B Glass; W Gassmann
Journal:  Clin Investig       Date:  1993-10

9.  All-trans-retinoic acid induces manganese superoxide dismutase in human neuroblastoma through NF-kappaB.

Authors:  Kinsley K Kiningham; Zina-Ann Cardozo; Carla Cook; Marsha P Cole; John C Stewart; Mariela Tassone; Mitchell C Coleman; Douglas R Spitz
Journal:  Free Radic Biol Med       Date:  2008-01-30       Impact factor: 7.376

10.  Molecular recognition of acute myeloid leukemia using aptamers.

Authors:  K Sefah; Z W Tang; D H Shangguan; H Chen; D Lopez-Colon; Y Li; P Parekh; J Martin; L Meng; J A Phillips; Y M Kim; W H Tan
Journal:  Leukemia       Date:  2009-01-08       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.